Citigroup Maintains Buy on Summit Therapeutics, Raises Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz maintains a Buy rating on Summit Therapeutics and raises the price target from $13 to $19.
September 09, 2024 | 3:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup analyst Yigal Nochomovitz has reaffirmed a Buy rating for Summit Therapeutics and increased the price target from $13 to $19, indicating a positive outlook for the stock.
The increase in the price target from $13 to $19 by a reputable analyst at Citigroup suggests a strong positive outlook for Summit Therapeutics. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100